Paper
Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer.
Published Dec 1, 2001 · R. Momparler, J. Ayoub
Lung cancer
Q1 SJR score
87
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Case Report
Highly CitedStudy Snapshot
5-AZA-CdR, a potent inhibitor of DNA methylation, shows potential in reactivating tumor suppressor genes and reversing tumorigenesis in advanced non-small cell lung cancer patients.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.
Methylation of the RARbeta P2 promoter leads to silencing of RARbeta2 and RARbeta4 expression in many lung cancers, and chemical demethylation may be a potential approach for lung cancer therapy.
2001·371citations·A. Virmani et al.·Journal of the National Cancer Institute
Journal of the National Cancer Institute
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Aberrant methylation of p16 and O6-methyl-guanine-DNA methyltransferase promoters in sputum can predict lung cancer up to 3 years before clinical diagnosis, offering a potential population-based screening approach for early detection.
2000·860citations·W. Palmisano et al.·Cancer research
Cancer research
2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
5-aza-CdR effectively increases fetal hemoglobin levels in sickle cell anemia patients who fail to respond to hydroxyurea treatment, potentially offering an alternative treatment option.
2000·163citations·M. Koshy et al.·Blood
Blood
Gemcitabine plus vinorelbine as first‐line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial
Gemcitabine and vinorelbine show potential as first-line chemotherapy for advanced nonsmall cell lung carcinoma, with a low toxicity profile and potential for improved response and survival rates.
2000·32citations·E. Bajetta et al.·Cancer
Cancer
The DNA methylation machinery as a therapeutic target.
DNA methylation plays a crucial role in controlling genomic processes and plays a role in cancer, making it a potential therapeutic target for pharmacological intervention.
2000·24citations·M. Szyf·Current drug targets
Current drug targets
Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2'-deoxycytidine in tumor cells using a single-nucleotide primer extension assay.
The modified assay accurately quantitates 5-AZA-CdR's inhibition of DNA methylation in tumor cells, providing valuable data for analyzing its therapeutic efficacy in cancer therapy.
2000·5citations·V. Bovenzi et al.·Analytical biochemistry
Analytical biochemistry
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
Inactivation of MGMT by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
2000·570citations·M. Esteller et al.·Cancer research
Cancer research
DNA methylation and cancer
DNA methylation plays an important role in gene expression control and tumorigenesis, and inhibitors of DNA methylation may be potential targets for chemotherapy in cancer patients.
2000·225citations·R. Momparler et al.·Journal of Cellular Physiology
Journal of Cellular Physiology
Caspase 8: The killer you can't live without
Understanding the role of MYCN and caspase 8 in neuroblastoma may lead to new treatment strategies.
2000·18citations·P. Juin et al.·Nature Medicine
Nature Medicine
Citations
···
···
···
···